The study found that that edoxaban, a once-daily direct factor Xa-inhibitor, met the primary efficacy endpoint of non-inferiority compared to warfarin for the prevention of stroke or systemic embolic events in patients with NVAF. In addition, edoxaban achieved superiority for the principal safety endpoint by showing significant reduction in major bleeding compared to warfarin.